The Chemotherapy Induced Neutropenia Market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy Induced Neutropenia: An Overview
Chemotherapy-Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The symptoms of CIN that most patients observe are chills or sweating, Sore throat, sores in the mouth, or a toothache, abdominal pain, pain near the anus, and others.
Chemotherapy Induced Neutropenia Market Key Facts
In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020.
In 2020, the highest number of cancer patients on chemotherapy was accounted by the US, making up to 691,906, while the EU5 countries accounted for 778,973 cancer patients on chemotherapy. Japan ranked second among 7MM countries, with 319,740 cancer patients on chemotherapy in 2020.
In 2020, the total number of cases of Chemotherapy Induced Neutropenia in the 7MM was 903,597. The US accounted for the majority of cases in the 7MM with 383,339 cases.
Among the European countries, Germany had the highest number of cases of Chemotherapy Induced Neutropenia with 96,877 cases, followed by the UK. On the other hand, Spain had the lowest number of CIN cases in 2020.
The Chemotherapy Induced Neutropenia market size of Neupogen and Neulasta was USD 216 million and USD 2,450 million in 2020 in the 7MM.
The Chemotherapy Induced Neutropenia market share of biologics is expected to decline owing to the entry of biosimilars as well as novel therapies.
Major key players leading the Chemotherapy Induced Neutropenia market size growth ahead include Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals, and others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chemotherapy Induced Neutropenia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Chemotherapy Induced Neutropenia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy Induced Neutropenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Chemotherapy Induced Neutropenia Market Report Provides the Epidemiological Analysis by-
Total number of Patients on Chemotherapy
Risk-specific Chemotherapy Patient Pool for Chemotherapy Induced Neutropenia
Total Incident Cases of Chemotherapy-Induced Neutropenia by Cancer-Type
Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to get launched during the study period. The analysis covers the Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy Induced Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Chemotherapy Induced Neutropenia Market Will Evolve by 2032 @
Some of the key companies in the Chemotherapy Induced Neutropenia (CIN) Therapeutics Market Include:
Myelo Therapeutics GmbH
Kyowa Hakko Kirin Co., Ltd.
And many others
Chemotherapy Induced Neutropenia (CIN) Therapies Covered in the Report Include:
EC-18: Enzychem Lifesciences
Neupogen (Filgrastim): Amgen
Plinabulin: BeyondSpring Pharmaceuticals
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chemotherapy Induced Neutropenia Competitive Intelligence Analysis
4. Chemotherapy Induced Neutropenia Market Overview at a Glance
5. Chemotherapy Induced Neutropenia Disease Background and Overview
6. Chemotherapy Induced Neutropenia Patient Journey
7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Chemotherapy Induced Neutropenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy Induced Neutropenia Unmet Needs
10. Key Endpoints of Chemotherapy Induced Neutropenia Treatment
11. Chemotherapy Induced Neutropenia Marketed Products
12. Chemotherapy Induced Neutropenia Emerging Drugs and Latest Therapeutic Advances
13. Chemotherapy Induced Neutropenia Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy Induced Neutropenia Market Outlook (In US, EU5, and Japan)
16. Chemotherapy Induced Neutropenia Access and Reimbursement Overview
17. KOL Views on the Chemotherapy Induced Neutropenia Market
18. Chemotherapy Induced Neutropenia Market Drivers
19. Chemotherapy Induced Neutropenia Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
“Chemotherapy induced Neutropenia Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Chemotherapy-induced Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States